Toxicity of nanomaterials to the eye

被引:56
作者
Prow, Tarl W. [1 ]
机构
[1] Univ Queensland, Therapeut Res Unit, Woolloongabba, Qld 4102, Australia
关键词
OCULAR DRUG-DELIVERY; EXPERIMENTAL AUTOIMMUNE UVEORETINITIS; COMPACTED DNA NANOPARTICLES; SERUM-ALBUMIN NANOPARTICLES; RETINAL-PIGMENT EPITHELIUM; SOLID LIPID NANOPARTICLES; CHITOSAN NANOPARTICLES; OPHTHALMIC APPLICATION; PLGA NANOPARTICLES; EUDRAGIT RS100(R);
D O I
10.1002/wnan.65
中图分类号
TB3 [工程材料学];
学科分类号
0805 ; 080502 ;
摘要
What do nanoparticles offer drug delivery to the eye that traditional formulations do not? The underlying concept of nanomedicine is that the nanomaterials have properties that their constituent components do not have. These unique properties are the benefit, but the cost can be more a complicated toxicology assessment. Ocular delivery of therapeutic nanoparticles has the potential to greatly increase the quality of life through maintaining our vision. The eye is composed of multiple tissue types, i.e., epithelium, muscle, immune cells, neural cells, and blood vessels, to name a few. Ocular diseases affect many of these tissues at once. Introduce novel therapeutic nanoparticles and determining mechanisms of toxicity becomes challenging. This review is a survey of what is known about toxicity in experimental nanoparticles for ocular therapeutics. Specific cases are chosen to illustrate a range of toxic effects of nanoparticles in the eye. There is a unique research opportunity for in-depth toxicology studies of nanoparticles in the eye. This has been made possible by the rapid development of therapeutic nanoparticles in the last few years. (C) 2009 John Wiley & Sons, Inc. WIREs Nanomed Nanobiotechnol 2010 2 317-333
引用
收藏
页码:317 / 333
页数:17
相关论文
共 65 条
[1]   Piroxicam nanoparticles for ocular delivery: Physicochemical characterization and implementation in endotoxin-induced uveitis [J].
Adibkia, Khosro ;
Shadbad, Mohammad Reza Siahi ;
Nokhodchi, Ali ;
Javadzedeh, Alireza ;
Barzegar-Jalali, Mohammad ;
Barar, Jaleh ;
Mohammadi, Ghobad ;
Omidi, Yadollah .
JOURNAL OF DRUG TARGETING, 2007, 15 (06) :407-416
[2]   Diclofenac-loaded biopolymeric nanosuspensions for ophthalmic application [J].
Agnihotri, Sagar M. ;
Vavia, Pradeep R. .
NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE, 2009, 5 (01) :90-95
[3]   Size-dependent disposition of nanoparticles and microparticles following subconjunctival administration [J].
Amrite, AC ;
Kompella, UB .
JOURNAL OF PHARMACY AND PHARMACOLOGY, 2005, 57 (12) :1555-1563
[4]   Chitosan based nanocarriers for indomethacin ocular delivery [J].
Badawi, Alia A. ;
El-Laithy, Hanan M. ;
El Qidra, Riad K. ;
El Mofty, Hala ;
El Dally, Mohamed .
ARCHIVES OF PHARMACAL RESEARCH, 2008, 31 (08) :1040-1049
[5]   Absence of histologic retinal toxicity of intravitreal nanogold in a rabbit model [J].
Bakri, Sophie J. ;
Pulido, Jose S. ;
Mukherjee, Priyabata ;
Marler, Ronald J. ;
Mukhopadhyay, Debabrata .
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2008, 28 (01) :147-149
[6]  
Bejjani R, 2005, MOL VIS, V11, P124
[7]   Localization of collagen XVIII and the endostatin portion of collagen XVIII in aged human control eyes and eyes with age-related macular degeneration [J].
Bhutto, IA ;
Kim, SY ;
McLeod, DS ;
Merges, C ;
Fukai, N ;
Olsen, BR ;
Lutty, GA .
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2004, 45 (05) :1544-1552
[8]   Ocular drug delivery targeting the retina and retinal pigment epithelium using polylactide nanoparticles [J].
Bourges, JL ;
Gautier, SE ;
Delie, F ;
Bejjani, RA ;
Jeanny, JC ;
Gurny, R ;
BenEzra, D ;
Behar-Cohen, FF .
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2003, 44 (08) :3562-3569
[9]   Eudragit RL100 nanoparticle system for the ophthalmic delivery of cloricromene [J].
Bucolo, C ;
Maltese, A ;
Maugeri, F ;
Busà, B ;
Puglisi, G ;
Pignatello, R .
JOURNAL OF PHARMACY AND PHARMACOLOGY, 2004, 56 (07) :841-846
[10]   Enhanced ocular anti-inflammatory activity of lbuprofen carried by an Eudragit RS100® nanoparticle suspension [J].
Bucolo, C ;
Maltese, A ;
Puglisi, G ;
Pignatello, R .
OPHTHALMIC RESEARCH, 2002, 34 (05) :319-323